Birendra Bhattarai, MD
Internal Medicine · Mount Dora, FLNPI 1851592802
Payments from drug & device makers
Across 225 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$564
- GSK$521
- Baxter Healthcare$399
- Novartis$324
- AstraZeneca$279
- Astellas Pharma US Inc$245
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,88286%
- Education$1002%
- Other$54412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $564 |
| GSK | 33 | $521 |
| Baxter Healthcare | 2 | $399 |
| Novartis | 20 | $324 |
| AstraZeneca | 15 | $279 |
| Astellas Pharma US Inc | 9 | $245 |
| AbbVie(2 entities) | 13 | $234 |
| Phathom Pharmaceuticals, Inc. | 3 | $231 |
| Welch Allyn | 3 | $165 |
| Pfizer | 9 | $154 |
| Sumitomo Pharma America, Inc. | 7 | $140 |
| Exact Sciences | 7 | $139 |
| Johnson & Johnson | 8 | $122 |
| Merck | 6 | $121 |
| Esperion Therapeutics, Inc. | 5 | $109 |
| Abbott | 6 | $105 |
| Amgen(2 entities) | 5 | $87 |
| Amarin Pharma, Inc. | 5 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $80 |
| Lilly USA, LLC | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $30 |
| Boehringer Ingelheim | 1 | $26 |
| Bardy Diagnostics, Inc. | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Biogen | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Novavax Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Millicent US Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Valeritas, Inc. | 1 | $12 |
How this compares
$4,526 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $189,457 |
| OzempicSemaglutide | 83 | $124,166 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $93,474 |
| JardianceEmpagliflozin | 67 | $92,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $69,874 |
| FarxigaDapagliflozin Propanediol | 58 | $59,140 |
| XareltoRivaroxaban | 46 | $41,303 |
| JanuviaSitagliptin Phosphate | 51 | $35,621 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 138 | $28,175 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $26,986 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 61 | $18,216 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $18,167 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $16,007 |
| Gabapentin | 441 | $14,651 |
| Spiriva HandihalerTiotropium Bromide | 19 | $14,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $154 | $189,457181 claims |
| Novo NordiskOzempic | $564 | $124,16683 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26 | $100,67779 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $521 | $88,041102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $279 | $79,937104 claims |
| MerckJanuvia, Janumet | $121 | $62,60777 claims |
| Johnson & JohnsonXarelto | $122 | $41,30346 claims |
| NovartisEntresto | $324 | $14,15311 claims |
| Astellas Pharma US IncMyrbetriq | $245 | $14,12520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Mount Dora
- Shirley NagelMount Dora$4.3M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.